EMA validates type II variation for Merck’s KEYTRUDA® (pembrolizumab) with Pemetrexed
Merck announced that following validation by the EMA, the centralized review process has begun for the company’s Type II Variation, which seeks approval for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with pemetrexed (ALIMTA®) and platinum chemotherapy for metastatic nonsquamous NSCLC. April 23, 2018